Stay updated with breaking news from Gary ingenito. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Catalyst Pharmaceuticals (NASDAQ:CPRX – Get Free Report) was upgraded by stock analysts at StockNews.com from a “hold” rating to a “buy” rating in a research note issued on Friday. Several other analysts also recently commented on CPRX. Oppenheimer reaffirmed an “outperform” rating and set a $29.00 target price on shares of Catalyst Pharmaceuticals in a […] ....
CORAL GABLES, Fla., Aug. 14, 2023 Catalyst Pharmaceuticals, Inc. , a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel. -Today at 08:06 am- MarketScreener ....
Operator: Greetings and welcome to the Catalyst Pharmaceuticals first quarter 2023 financial results conference call. At this time, all participants are in a listen-only mode. ....
Catalyst Pharma (CPRX) Announces Recent Third-Party Publication Journal Epilepsia Showing Perampanel Demonstrated High Efficacy in Patients with Rare Genetic Epilepsies streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Prospera Financial Services Inc reduced its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Get Rating) by 13.0% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 30,804 shares of the biopharmaceutical company’s stock after selling 4,586 shares during the quarter. […] ....